Back to top

Image: Bigstock

MannKind Corporation

Read MoreHide Full Article

MannKind reported a narrower loss in the third quarter of 2015 than the year-ago period. The company’s decision to choose a large company like Sanofi as a partner for Afrezza is highly encouraging. Sanofi’s progress on commercializing Afrezza by expanding the sales force is a big positive for MannKind. Although Afrezza enjoys several advantages over traditional needle-based insulin therapy, several limitations in the drug’s label are concerning. We remain worried about the company’s dependence on a single product for growth.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

MannKind Corporation (MNKD) - free report >>

Published in